KRAS G12C inhibitor
KRAS G12C covalent inhibitor
- Locks the mutant in its inactive GDP-bound state
- Silences the oncogenic driver
- Works only for the specific G12C mutation
- Covalently locks KRAS G12C in its inactive state
- The first drug against a target long considered undruggable
Drugs with this mechanism (1)
- Sotorasib — First KRAS G12C inhibitor—proof that a formerly undruggable target could be reached.
All mechanisms · Open KRAS G12C inhibitor in the interactive console ↗